Market Overview

MetaStat Welcomes Renato T. Skerlj, Ph.D., Accomplished Drug Developer to Its Scientific and Clinical Advisory Board


MetaStat, Inc. (OTCQB:MTST), a personalized medicine company
developing therapeutic and diagnostic treatment solutions for cancer
patients, announced today accomplished drug developer, Renato T. Skerlj,
Ph.D., has joined the company as a member of its Scientific and Clinical
Advisory Board.

"MetaStat's proprietary driver-based pan-cancer biomarkers are exciting
targets for cancer drug development. They represent the promise of
personalized medicine and the potential for new targeted cancer
therapies that address major treatment challenges facing oncologists and
their patients," said Dr. Skerlj.

"I am especially delighted to welcome Dr. Skerlj to MetaStat's SAB to
help with our internal anti-metastatic drug development program.
Renato's knowledge, experience and successful track record are
invaluable assets to help us efficiently advance our small molecule
program that is aimed at preventing aggressive cancer from spreading,"
stated Douglas. A. Hamilton, MetaStat's President and CEO.

Dr. Skerlj serves as Vice President of Drug Discovery and Preclinical
Development at Lysosomal Therapeutics Inc. Dr. Skerlj is a co-founder
and a Member of Scientific Advisory Board of X4 Pharmaceuticals Inc. and
co-founder of Noliva Therapeutics. He has over 25 years of
pharmaceutical experience in drug development resulting in two marketed
drugs: Invanz® and Mozobil® and multiple drugs in
clinical development. Previously, Dr. Skerlj served as the Head of Small
Molecule Discovery at Genzyme, prior to its acquisition by Sanofi. He
served as Vice President of Chemistry for AnorMED Inc., a
publicly-traded company acquired by Genzyme for $580 million in 2006.
Prior to AnorMED Inc., Dr. Skerlj served as a Senior Research Chemist at
Merck & Co., Inc. and Senior Scientist at Johnson Matthey's biomedical
research group. Dr. Skerlj earned his doctorate from the University of
British Columbia and completed a fellowship at the University of Oxford
in Dr. Stephen Davies' laboratory.

About MetaStat, Inc.

MetaStat is a biotechnology company focused on discovering and
developing personalized therapeutic and diagnostic treatment solutions
for cancer patients. Our Mena isoform "driver-based" diagnostic
biomarkers also serve as novel therapeutic targets for anti-metastatic
drugs. MetaStat is developing therapeutic product candidates and paired
companion diagnostics based on a novel approach that makes the Mena
isoform protein a druggable target. Our core expertise includes an
understanding of the mechanisms and pathways that drive tumor cell
invasion and metastasis, as well as drug resistance to certain targeted
therapies and cytotoxic chemotherapies. MetaStat is based in Boston, MA.

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the company's Form 10-K and its other filings filed
with the Securities and Exchange Commission. You should consider these
factors in evaluating the forward-looking statements included herein,
and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the
company undertakes no obligation to update such statements.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at